Drug Profile
BOS 356
Alternative Names: BOS-356; GSK 3008356Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Boston Pharmaceuticals; GSK
- Class Antiacnes; Small molecules
- Mechanism of Action Diacylglycerol O acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne vulgaris; Unspecified
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Acne-vulgaris in Canada (Topical, Gel)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Acne-vulgaris in USA (Topical, Gel)
- 11 Nov 2020 Boston Pharmaceuticals completes a phase I trial in Acne in USA, Canada (NCT04163263)